Asunaprevir/daclatasvir

Asunaprevir/daclatasvir Reactions 1680, p60 - 2 Dec 2017 Various toxicities: 4 case reports In a single centre retrospective longitudinal observational study, four elderly patients [sexes and specific ages not stated] were described, who developed elevated serum AST and ALT levels (1 patient), fever and fatigue (1 patient), appetite loss and nausea (1 patient) and fatigue and dysphasia (1 patient) during treatment with daclatasvir and asunaprevir [times to reactions onsets and outcomes not stated]. All the patients had a history of chronic hepatitis C virus genotype 1b infection and liver dysfunction. Out of these four patients, three patients were included in chronic kidney disease (CKD) group, and the remaining patient was included in non-CKD group of the retrospective study. All the patients received antiviral therapy, which consisted of oral daclatasvir 60mg once daily after breakfast, and oral asunaprevir 100mg twice daily after breakfast and after supper. Various parameters including serum AST and ALT levels were routinely monitored. Subsequently, the patients developed elevated serum AST and ALT levels (n=1), fever and fatigue (n=1), appetite loss and nausea (n=1) and fatigue and dysphasia (n=1). The antiviral therapy was discontinued in all four patients. Author comment: "Adverse effects were comparable between the two groups." "The patients received oral administration of 60mg [daclatasvir] once a day after breakfast and 100mg [asunaprevir] twice a day". "Three patients in the CKD group withdrew the treatment due to the elevation in serum AST and ALT levels in 1 patient, fever and fatigue in 1, and appetite loss and nausea in 1". "[I]n the non-CKD group. . .fatigue and dysphasia in 1". Morisawa N, et al. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clinical and Experimental Nephrology 21: 818-824, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1007/s10157-016-1348-7 - Japan 803283897 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Asunaprevir/daclatasvir

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/asunaprevir-daclatasvir-owiOgpUPxb
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38991-0
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p60 - 2 Dec 2017 Various toxicities: 4 case reports In a single centre retrospective longitudinal observational study, four elderly patients [sexes and specific ages not stated] were described, who developed elevated serum AST and ALT levels (1 patient), fever and fatigue (1 patient), appetite loss and nausea (1 patient) and fatigue and dysphasia (1 patient) during treatment with daclatasvir and asunaprevir [times to reactions onsets and outcomes not stated]. All the patients had a history of chronic hepatitis C virus genotype 1b infection and liver dysfunction. Out of these four patients, three patients were included in chronic kidney disease (CKD) group, and the remaining patient was included in non-CKD group of the retrospective study. All the patients received antiviral therapy, which consisted of oral daclatasvir 60mg once daily after breakfast, and oral asunaprevir 100mg twice daily after breakfast and after supper. Various parameters including serum AST and ALT levels were routinely monitored. Subsequently, the patients developed elevated serum AST and ALT levels (n=1), fever and fatigue (n=1), appetite loss and nausea (n=1) and fatigue and dysphasia (n=1). The antiviral therapy was discontinued in all four patients. Author comment: "Adverse effects were comparable between the two groups." "The patients received oral administration of 60mg [daclatasvir] once a day after breakfast and 100mg [asunaprevir] twice a day". "Three patients in the CKD group withdrew the treatment due to the elevation in serum AST and ALT levels in 1 patient, fever and fatigue in 1, and appetite loss and nausea in 1". "[I]n the non-CKD group. . .fatigue and dysphasia in 1". Morisawa N, et al. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clinical and Experimental Nephrology 21: 818-824, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1007/s10157-016-1348-7 - Japan 803283897 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off